Flag of the European Union EU Clinical Trials Register Help

Clinical trials for yondelis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43883   clinical trials with a EudraCT protocol, of which   7296   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: yondelis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-002276-17 Sponsor Protocol Number: ET-B-025-02 Start Date*: 2006-08-24
    Sponsor Name:Pharma Mar SA, Sociedad Unipersonal
    Full Title: Phase II Study of Yondelis® in Men with Advanced Prostate Carcinoma Estudio fase II con Yondelis en hombres con cáncer de próstata avanzado
    Medical condition: Advanced Prostate Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10036909 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-005276-16 Sponsor Protocol Number: ET743-OVA-301 Start Date*: 2005-10-27
    Sponsor Name:Pharma Mar S.A.
    Full Title: An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer.
    Medical condition: Advanced relapsed ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000035-25 Sponsor Protocol Number: ET-B-028-06 Start Date*: 2007-07-13
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis®) in Patients with Localized Myxoid / Round Cell Liposarcoma
    Medical condition: Localized myxoid / round cell liposarcoma previously untreated with chemotherapy or radiation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024630 Liposarcoma non-metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012430-70 Sponsor Protocol Number: CSET 2008/1485 Start Date*: 2010-05-12
    Sponsor Name:Institut Gustave Roussy
    Full Title: Etude de phase II multicentrique étudiant l’efficacité de la doxorubicine associée à de la trabectedine (Yondelis) en première ligne dans le traitement des patients présentant un léiomyosarcome mé...
    Medical condition: Leimyosarcomes des tissus mous et uterins métastatiques et/ou en rechute inopérable
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024191 Leiomyosarcoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002106-29 Sponsor Protocol Number: ET-743-STS-201 Start Date*: 2005-05-13
    Sponsor Name:Pharma Mar SA Unipersonal
    Full Title: A Randomized, Multicenter, Open-label Study of YONDELIS ™ (ET-743 ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 weeks vs. q3 Weeks) in Subjects With Locally Advanced or Me...
    Medical condition: Advanced or Metastatic Liposarcoma or Leiomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    5.0 10039494 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022968-13 Sponsor Protocol Number: ET-B-031-10 Start Date*: 2011-03-16
    Sponsor Name:Pharma Mar, S.A. Sociedad Unipersonal
    Full Title: Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Receptors Positive, HER2 Negative, Advanced Breast Carcinoma, Overexpressing or Underexpressing Xeroderm...
    Medical condition: Advanced Breast Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006204 Breast carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002411-14 Sponsor Protocol Number: 12576/15 Start Date*: 2015-07-28
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: TRABECTEDIN SINGLE AGENT IN PARTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) PATIENTS: A PROSPECTIVE, PHASE II STUDY
    Medical condition: ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10051938 Ovarian adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011041-12 Sponsor Protocol Number: ET-A-018-09 Start Date*: 2009-07-23
    Sponsor Name:Pharma Mar S.A.
    Full Title: Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité.
    Medical condition: Pretreated Advanced Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005153-12 Sponsor Protocol Number: MITO26 Start Date*: 2019-07-17
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Phase II trial on trabectedin in the treatment of advanced uterine and ovarian carcinosarcoma (Cs) – MITO 26
    Medical condition: advanced ovarian and uterine carcinosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052204 Ovarian carcinosarcoma LLT
    20.0 100000004864 10007508 Carcinosarcoma uterus LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002326-11 Sponsor Protocol Number: ET-C-002-07 Start Date*: 2008-10-22
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS)
    Medical condition: Translocation-Related Sarcomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000794-31 Sponsor Protocol Number: ET-B-027-06 Start Date*: 2007-08-01
    Sponsor Name:Pharma Mar, S.A.
    Full Title: Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis®) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-), HER2 overexpressing tumors and BRCA...
    Medical condition: Progressive metastatic breast cancer previously treated in the following subpopulation of patients: Group A: Triple negative phenotype: Estrogen Receptor, Progesterone Receptor and HER-2 negative s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) IT (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004808-34 Sponsor Protocol Number: ET743-OVC-3006 Start Date*: 2013-07-11
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or...
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-006681-15 Sponsor Protocol Number: ET-B-029-07 Start Date*: 2008-08-26
    Sponsor Name:Pharma Mar, S.A.
    Full Title: Ensayo Clínico de Fase II de Trabectedina tras Progresión a Terapia Antitumoral basada en Platino en Pacientes con Cáncer No Microcítico de Pulmón (CNMP) Avanzado con Sobreexpresión de XPG y/o ERCC...
    Medical condition: Cáncer no microcítico de pulmón (CNMP) avanzado
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-024287-17 Sponsor Protocol Number: PACT-18 Start Date*: 2011-02-03
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Salvage therapy with trabectidin in metastatic pancreatic adenocarcinoma: a single-arm phase II trial.
    Medical condition: metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051971 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006330-16 Sponsor Protocol Number: IRFMN-MPM-6077 Start Date*: 2013-05-23
    Sponsor Name:Istituto di ricerche farmacologiche "Mario Negri"
    Full Title: ATREUS TRIAL A PHASE II STUDY ON THE ACTIVITY OF TRABECTEDIN IN PRETREATED EPITHELIOID OR BIPHASIC/SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Medical condition: Malignant Pleural Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001298-17 Sponsor Protocol Number: 362/11 Start Date*: 2012-04-05
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Phase II study on ET-743 in BRCA1 and BRCA2 mutation carrie and BRCAness phenotype advanced ovarian cancer patients.
    Medical condition: advaced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033129 Ovarian neoplasms malignant (excl germ cell) HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000230-35 Sponsor Protocol Number: 014-FPO18 Start Date*: 2018-10-17
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced ...
    Medical condition: platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005428-14 Sponsor Protocol Number: ISG-STS-TRAB-2012 Start Date*: 2014-04-16
    Sponsor Name:Italian Sarcoma Group
    Full Title: A Phase II study on Trabectedin in advanced retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma
    Medical condition: Advanced retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024627 Liposarcoma PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073135 Dedifferentiated liposarcoma PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024189 Leiomyosarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004497-10 Sponsor Protocol Number: ISG-TOMAS-2 Start Date*: 2019-11-12
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: Phase 2 randomized trial of trabectedin + olaparib vs. trabectedin in advanced, metastatic or unresectable soft tissue sarcoma after failure of standard treatments
    Medical condition: Advanced, metastatic or unresectable soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003733-41 Sponsor Protocol Number: ISG-MCS Start Date*: 2021-02-23
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: Phase II study on Trabectedin in advanced rearranged Mesenchymal chondrosarcoma (MCS)
    Medical condition: Patients with advanced, histological and molecularly (presence of the HEY1-NCOA2 fusion) centrally confirmed diagnosis of MCS, with an evidence of RECIST progression within the 6 months prior to st...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 21 06:09:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA